Costas G Thomopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6459015/publications.pdf Version: 2024-02-01

		101543	30922
173	11,181	36	102
papers	citations	h-index	g-index
191 all docs	191 docs citations	191 times ranked	14045 citing authors

#	Article	lF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. Journal of Hypertension, 2014, 32, 2285-2295.	0.5	267
3	Effects of blood pressure lowering on outcome incidence in hypertension. Journal of Hypertension, 2016, 34, 613-622.	0.5	254
4	Effects of blood pressure lowering on outcome incidence in hypertension. Journal of Hypertension, 2015, 33, 195-211.	0.5	221
5	Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Advances in Nutrition, 2020, 11, 1150-1160.	6.4	195
6	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. Journal of Hypertension, 2017, 35, 922-944.	0.5	173
7	Effects of blood pressure lowering on outcome incidence in hypertension. Journal of Hypertension, 2014, 32, 2296-2304.	0.5	151
8	Randomized Controlled Trials of Blood Pressure Lowering in Hypertension. Circulation Research, 2015, 116, 1058-1073.	4.5	131
9	Effects of blood pressure-lowering on outcome incidence in hypertension. Journal of Hypertension, 2015, 33, 1321-1341.	0.5	123
10	Effects of blood pressure lowering on outcome incidence in hypertension. Journal of Hypertension, 2014, 32, 2305-2314.	0.5	106
11	Assisted reproductive technology and pregnancy-related hypertensive complications: a systematic review. Journal of Human Hypertension, 2013, 27, 148-157.	2.2	103
12	Periodontitis and blood pressure: The concept of dental hypertension. Atherosclerosis, 2011, 219, 1-9.	0.8	100
13	Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. European Heart Journal, 2007, 28, 1162-1169.	2.2	92
14	Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure. Journal of Hypertension, 2017, 35, 2150-2160.	0.5	84
15	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. Journal of Hypertension, 2018, 36, 1622-1636.	0.5	77
16	Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure – meta-analyses of randomized trials. Journal of Hypertension, 2016, 34, 373-384.	0.5	75
17	Effects of blood-pressure-lowering treatment in hypertension. Journal of Hypertension, 2016, 34, 1921-1932.	0.5	74
18	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity. Journal of Hypertension, 2014, 32, 415-422.	0.5	70

COSTAS G THOMOPOULOS

#	Article	IF	CITATIONS
19	Hypertension crisis. Blood Pressure, 2010, 19, 328-336.	1.5	69
20	Effects of blood pressure lowering treatment in hypertension. Journal of Hypertension, 2016, 34, 1451-1463.	0.5	69
21	Increased nighttime blood pressure or nondipping profile for prediction of cardiovascular outcomes. Journal of Human Hypertension, 2011, 25, 281-293.	2.2	66
22	Association of Obstructive Sleep Apnea With Urinary Albumin Excretion in Essential Hypertension: A Cross-sectional Study. American Journal of Kidney Diseases, 2008, 52, 285-293.	1.9	62
23	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. Journal of Hypertension, 2018, 36, 1637-1647.	0.5	59
24	Association of Passive Smoking With Masked Hypertension in Clinically Normotensive Nonsmokers. American Journal of Hypertension, 2009, 22, 853-859.	2.0	53
25	Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. Journal of Hypertension, 2009, 27, 744-752.	0.5	53
26	ADMA, C-Reactive Protein, and Albuminuria in Untreated Essential Hypertension: A Cross-sectional Study. American Journal of Kidney Diseases, 2010, 55, 1050-1059.	1.9	53
27	Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. Journal of Clinical Hypertension, 2019, 21, 546-554.	2.0	47
28	Orthostatic hypertension: From pathophysiology to clinical applications and therapeutic considerations. Journal of Clinical Hypertension, 2019, 21, 426-433.	2.0	47
29	Mediterranean diet and blood pressure reduction in adults with and without hypertension: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition, 2021, 40, 3191-3200.	5.0	46
30	The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus. Journal of Hypertension, 2019, 37, 1334-1343.	0.5	43
31	The interplay between haemodynamic load, brain natriuretic peptide and left atrial size in the early stages of essential hypertension. Journal of Hypertension, 2006, 24, 965-972.	0.5	42
32	Combination drug treatment in hypertension. Pharmacological Research, 2017, 125, 266-271.	7.1	42
33	Exercise Blood Pressure Response, Albuminuria, and Arterial Stiffness in Hypertension. American Journal of Medicine, 2008, 121, 894-902.	1.5	41
34	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. Journal of Hypertension, 2010, 28, 2299-2308.	0.5	40
35	Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and metaâ€analysis. Journal of Clinical Hypertension, 2017, 19, 173-183.	2.0	40
36	Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea. Journal of Hypertension, 2015, 33, 393-400.	0.5	39

#	Article	IF	CITATIONS
37	Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. International Journal of Cardiology, 2013, 168, 987-992.	1.7	38
38	A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. Journal of Hypertension, 2016, 34, 2127-2135.	0.5	37
39	Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. Journal of Hypertension, 2020, 38, 1669-1681.	0.5	36
40	Comparative Prognostic Role of Nighttime Blood Pressure and Nondipping Profile on Renal Outcomes. American Journal of Nephrology, 2011, 33, 277-288.	3.1	34
41	Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. Journal of Human Hypertension, 2008, 22, 501-508.	2.2	32
42	Drug-resistant hypertensive patients responding to multielectrode renal denervation exhibit improved heart rate dynamics and reduced arrhythmia burden. Journal of Human Hypertension, 2014, 28, 587-593.	2.2	31
43	Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTNâ,,¢ I first-in-human study using a multi-electrode ablation system. International Journal of Cardiology, 2015, 201, 345-350.	1.7	31
44	Managing hypertension in obstructive sleep apnea: the interplay of continuous positive airway pressure, medication and chronotherapy. Journal of Hypertension, 2010, 28, 875-882.	0.5	30
45	Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnea. Journal of Hypertension, 2013, 31, 352-360.	0.5	30
46	Masked Hypertension and Atherogenesis: The Impact on Adiponectin and Resistin Plasma Levels. Journal of Clinical Hypertension, 2009, 11, 61-65.	2.0	29
47	Association of nighttime hypertension with central arterial stiffness and urinary albumin excretion in dipper hypertensive subjects. Hypertension Research, 2011, 34, 120-125.	2.7	26
48	Obstructive sleep apnoea syndrome is associated with enhanced sub-clinical inflammation and asymmetric dimethyl-arginine levels in hypertensives. Journal of Human Hypertension, 2009, 23, 65-67.	2.2	25
49	Wearable blood pressure measurement devices and new approaches in hypertension management: the digital era. Journal of Human Hypertension, 2022, 36, 945-951.	2.2	25
50	Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots. Current Vascular Pharmacology, 2017, 16, 15-22.	1.7	24
51	Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 384-393.	3.0	24
52	Free Leptin Is Associated With Masked Hypertension in Nonobese Subjects. Hypertension, 2009, 53, 965-972.	2.7	23
53	Resistant Hypertension and Obstructive Sleep Apnea: The Sparring Partners. International Journal of Hypertension, 2011, 2011, 1-5.	1.3	23
54	Association of resistin and adiponectin with different clinical blood pressure phenotypes. Journal of Human Hypertension, 2011, 25, 38-46.	2.2	23

#	Article	IF	CITATIONS
55	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure. Journal of Hypertension, 2017, 35, 2138-2149.	0.5	23
56	The conjoint detrimental effect of chronic periodontal disease and systemic inflammation on asymmetric dimethyl-arginine in untreated hypertensive subjects. Atherosclerosis, 2010, 208, 258-263.	0.8	20
57	Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy. Journal of Hypertension, 2015, 33, 346-353.	0.5	20
58	Association of QT dispersion with mortality and arrhythmic events—A metaâ€analysis of observational studies. Journal of Arrhythmia, 2020, 36, 105-115.	1.2	19
59	Impact of Waist Circumference on Cardiac Phenotype in Hypertensives According to Gender. Obesity, 2009, 17, 177-182.	3.0	18
60	Effect of mineralocorticoid antagonists on blood pressure lowering. Journal of Hypertension, 2018, 36, 987-994.	0.5	17
61	Impact of major earthquakes on the incidence of acute coronary syndromes – A systematic review of the literature. Hellenic Journal of Cardiology, 2018, 59, 262-267.	1.0	16
62	Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study. International Journal of Cardiology, 2015, 180, 237-242.	1.7	15
63	Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension. Current Vascular Pharmacology, 2019, 17, 180-190.	1.7	15
64	Metabolic syndrome and exaggerated blood pressure response to exercise in newly diagnosed hypertensive patients. European Journal of Preventive Cardiology, 2012, 19, 467-473.	1.8	14
65	Effects of Hypertension, Diabetes Mellitus, Obesity and Other Factors on Kidney Haemodynamics. Current Vascular Pharmacology, 2014, 12, 537-548.	1.7	14
66	Late complications of heart transplantation: an 11-year experience. Heart and Vessels, 1999, 14, 272-276.	1.2	13
67	Impaired Glucose Metabolism and the Exaggerated Blood Pressure Response to Exercise Treadmill Testing in Normotensive Patients. Journal of Clinical Hypertension, 2009, 11, 627-635.	2.0	13
68	Effect of Lowâ€Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Metaâ€Analyses, and Metaâ€Regression Analyses of Randomized Trials. Clinical Cardiology, 2015, 38, 763-769.	1.8	12
69	Impact of baseline renal function on allâ€cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and metaâ€analysis. Journal of Arrhythmia, 2017, 33, 417-423.	1.2	12
70	Attended Versus Unattended Automated Office Blood Pressure: A Systematic Review and Meta-analysis. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 293-303.	2.2	12
71	Periodontitis and coronary artery disease: a questioned association between periodontal and vascular plaques. American Journal of Cardiovascular Disease, 2011, 1, 76-83.	0.5	12
72	Overview of salt restriction in the Dietary Approaches to Stop Hypertension (DASH) and the Mediterranean diet for blood pressure reduction. Reviews in Cardiovascular Medicine, 2022, 23, 1.	1.4	12

#	Article	IF	CITATIONS
73	Electrical stimulation of the renal arterial nerves does not unmask the blindness of renal denervation procedure in swine. International Journal of Cardiology, 2014, 176, 1061-1063.	1.7	11
74	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension. Journal of Hypertension, 2017, 35, 1750-1757.	0.5	11
75	Treatment Thresholds and Targets in Hypertension. Hypertension, 2018, 71, 966-968.	2.7	11
76	Best antihypertensive strategies to improve blood pressure control in Latin America. Journal of Hypertension, 2018, 36, 208-220.	0.5	11
77	Antidiabetic drugs and blood pressure changes. Pharmacological Research, 2020, 161, 105108.	7.1	11
78	Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressure–Lowering Treatment on Clinical Outcomes. Hypertension, 2022, 79, 491-504.	2.7	11
79	Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? A critical review. Journal of Hypertension, 2022, 40, 839-846.	0.5	11
80	Acute Effects of Electronic and Tobacco Cigarette Smoking on Sympathetic Nerve Activity and Blood Pressure in Humans. International Journal of Environmental Research and Public Health, 2022, 19, 3237.	2.6	11
81	Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Current Vascular Pharmacology, 2014, 12, 55-62.	1.7	10
82	Metformin and blood pressure lowering. Journal of Hypertension, 2017, 35, 27-28.	0.5	10
83	Left Ventricular Mass Index as a Predictor of New-Onset Microalbuminuria in Hypertensive Subjects: A Prospective Study. American Journal of Hypertension, 2012, 25, 1195-1201.	2.0	9
84	A Hypertensive Response to Exercise Is Prominent in Patients With Obstructive Sleep Apnea and Hypertension: A Controlled Study. Journal of Clinical Hypertension, 2013, 15, 497-502.	2.0	9
85	Nighttime vs. daytime blood pressure as a predictor of changes in left ventricular mass in hypertensive subjects. Hypertension Research, 2013, 36, 967-971.	2.7	9
86	Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8â€yearâ€followâ€up study. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 866-869.	1.9	9
87	Impact of ranolazine on ventricular arrhythmias – A systematic review. Journal of Arrhythmia, 2018, 34, 124-128.	1.2	9
88	Predictors of Adverse Outcomes in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. Cardiology in Review, 2019, 27, 189-197.	1.4	9
89	New-onset diabetes and cardiovascular events in essential hypertensives: A 6-year follow-up study. International Journal of Cardiology, 2011, 153, 154-158.	1.7	8
90	Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis. Heart Failure Reviews, 2018, 23, 547-553.	3.9	8

COSTAS G THOMOPOULOS

#	Article	IF	CITATIONS
91	Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG. Current Vascular Pharmacology, 2017, 15, 457-468.	1.7	8
92	Periodontal Disease Severity and Urinary Albumin Excretion in Middle-Aged Hypertensive Patients. American Journal of Cardiology, 2011, 107, 52-58.	1.6	7
93	Erectile Dysfunction and Target Organ Damage in the Early Stages of Hypertension. Journal of Clinical Hypertension, 2013, 15, 644-649.	2.0	7
94	Addressing delays in the diagnosis of pheochromocytoma/paraganglioma. Expert Review of Endocrinology and Metabolism, 2019, 14, 359-363.	2.4	7
95	Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables. Journal of Hypertension, 2019, 37, 1939-1949.	0.5	7
96	Monotherapy vs combination treatments of different complexity: a meta-analysis of blood pressure lowering randomized outcome trials. Journal of Hypertension, 2021, 39, 846-855.	0.5	7
97	Global longitudinal strain predicts responders after cardiac resynchronization therapy—a systematic review and meta-analysis. Heart Failure Reviews, 2022, 27, 827-836.	3.9	7
98	Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. Journal of Geriatric Cardiology, 2021, 18, 783-795.	0.2	7
99	Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. Expert Opinion on Therapeutic Targets, 2011, 15, 1347-1353.	3.4	6
100	Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?. Current Vascular Pharmacology, 2017, 16, 61-65.	1.7	6
101	Renal Denervation for Sleep Apnea and Resistant Hypertension: Alternative or Complementary to Effective Continuous Positive Airway Pressure Treatment?. Hypertension, 2011, 58, e191; author reply e192.	2.7	5
102	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. European Journal of Internal Medicine, 2019, 69, 1-7.	2.2	5
103	Sleep Apnea: Secondary Cause or Risk Factor for Hypertension?. Journal of Clinical Hypertension, 2012, 14, 405-406.	2.0	4
104	Resistant Hypertension: A Real Entity or a Phantom Diagnosis?. Journal of Clinical Hypertension, 2015, 17, 578-579.	2.0	4
105	A single-center, prospective, observational study on maternal smoking during pregnancy in Greece: The HELENA study. Tobacco Prevention and Cessation, 2021, 7, 1-9.	0.4	4
106	Obstructive sleep apnoea and hypertension: a growing clinical challenge. Hellenic Journal of Cardiology, 2008, 49, 299-302.	1.0	4
107	Masked hypertension unfavourably affects haemostasis parameters. Blood Pressure, 2011, 20, 218-221.	1.5	3
108	Impaired exercise tolerance is associated with increased urine albumin excretion in the early stages of essential hypertension. European Journal of Preventive Cardiology, 2012, 19, 452-459.	1.8	3

#	Article	IF	CITATIONS
109	Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnoea. Journal of Hypertension, 2014, 32, 2279-2280.	0.5	3
110	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. American Journal of Cardiology, 2020, 125, 887-893.	1.6	3
111	Impact of renal sympathetic denervation on cardiac magnetic resonance-derived cardiac indices in hypertensive patients – A meta-analysis. Journal of Cardiology, 2021, 78, 314-321.	1.9	3
112	Metabolic Effects of Renal Denervation. Current Clinical Pharmacology, 2013, 8, 206-211.	0.6	3
113	Sleep disorders and brain MRI as early indicators of subclinical hepatic encephalopathy. Hepato-Gastroenterology, 2006, 53, 51-4.	0.5	3
114	Free Leptin Predicts Incident (Clinic) Hypertension in a Danish Cohort. American Journal of Hypertension, 2010, 23, 814-814.	2.0	2
115	Cotinine and Blood Pressure Levels: Variability Omitted Once Again. Hypertension, 2013, 61, e41.	2.7	2
116	Outcome standardization to blood pressure reduction in meta-analyses. Journal of Hypertension, 2018, 36, 31-33.	0.5	2
117	Perioperative SBP changes during orthopedic surgery in the elderly. Journal of Hypertension, 2019, 37, 1705-1713.	0.5	2
118	P4388Acute detrimental effects of e-cigarette and tobacco cigarette smoking on blood pressure and sympathetic nerve activity in healthy subjects. European Heart Journal, 2019, 40, .	2.2	2
119	The new guidelines for hypertension: Navigating between Scylla and Charybdis of clinical practice. Hellenic Journal of Cardiology, 2020, 61, 127-128.	1.0	2
120	Do really statins reduce blood pressure?. Journal of Hypertension, 2020, 38, 408-411.	0.5	2
121	Rationale and Design of the ACS-BP Study: Prognostic Value of In-Hospital Blood Pressure and Indices of Atherosclerosis in Acute Coronary Syndromes. Current Vascular Pharmacology, 2021, 19, 438-443.	1.7	2
122	Isolated diastolic vs. systolic hypertension phenotypes and outcomes: prospective cohort of newly diagnosed individuals with hypertension. Journal of Hypertension, 2021, 39, 2001-2008.	0.5	2
123	Fatty liver index and hypertension-mediated organ damage in never-treated hypertensive patients without diabetes mellitus. Journal of Hypertension, 2021, 39, 2470-2477.	0.5	2
124	Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials. European Journal of Internal Medicine, 2022, 97, 78-85.	2.2	2
125	Carotid sinus stimulation responses are related with arterial elastic properties in hypertensive subjects. American Journal of Hypertension, 2003, 16, 914-918.	2.0	1
126	Changes of Metalloproteinases Profile in Patients With Masked Hypertension. Angiology, 2009, 60, 757-762.	1.8	1

COSTAS G THOMOPOULOS

#	Article	IF	CITATIONS
127	Pharmacological Therapy for Hypertensive Children: An "Additional Bypass―of Lifestyle Interventions. Hypertension, 2010, 56, e19; author reply e20.	2.7	1
128	Unmasking True Resistant Hypertension: Is the Real-World Resistance Just Revealed?. Hypertension, 2011, 58, e5; author reply e6.	2.7	1
129	The â€~pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study. Journal of Human Hypertension, 2011, 25, 401-402.	2.2	1
130	Nighttime Blood Pressure in Diabetes: Better Treat It Than Leave It. American Journal of Hypertension, 2012, 25, 279-279.	2.0	1
131	Resting Energy Expenditure and Blood Pressure: Evidence of Perpetual Association. Journal of Clinical Hypertension, 2014, 16, 166-167.	2.0	1
132	Morning hypertension in Asian populations. Journal of Clinical Hypertension, 2018, 20, 45-46.	2.0	1
133	Benefits and Risks of Antihypertensive Treatment. Circulation, 2018, 137, 144-147.	1.6	1
134	P611 A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GO-LIFE study. Journal of Crohn's and Colitis, 2019, 13, S422-S422.	1.3	1
135	Legacy effect on mortality in antihypertensive drug comparison trials. Journal of Hypertension, 2019, 37, 1532-1534.	0.5	1
136	Antihypertensive treatment escalation. Journal of Hypertension, 2019, 37, 1587-1589.	0.5	1
137	Reninangiotensin system blockers and the risk of critical or fatal coronavirus disease 2019 in African Americans. Journal of Hypertension, 2020, 38, 2384-2386.	0.5	1
138	Safety of catheter ablation of atrial fibrillation without pre†or periâ€procedural imaging for the detection of left atrial thrombus in the era of uninterrupted anticoagulation. Journal of Arrhythmia, 2021, 37, 28-32.	1.2	1
139	Left ventricular mass versus pulse wave velocity as predictors of coronary artery disease in hypertensive patients: data from a 6-year-follow-up study. Journal of Human Hypertension, 2021, , .	2.2	1
140	Peri-Procedural Care of Renal Nerve Ablation Candidates. Current Clinical Pharmacology, 2013, 8, 217-223.	0.6	1
141	Non-alcoholic fatty liver disease, diabetes medications and blood pressure. World Journal of Diabetes, 2021, 12, 1809-1811.	3.5	1
142	Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: A meta-analysis of outcome trials. Diabetes Research and Clinical Practice, 2021, 182, 109147.	2.8	1
143	Mild chronic hypertension in pregnancy: to treat or wait?. Blood Pressure, 2022, 31, 121-124.	1.5	1
144	ESTABLISHING THE LINKS BETWEEN THE SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS, ASYMMETRIC DIMETHYLARGININE AND LOW-GRADE INFLAMMATION IN ESSENTIAL HYPERTENSION. Journal of the American College of Cardiology, 2010, 55, A169.E1582.	2.8	0

#	Article	IF	CITATIONS
145	Exercise blood pressure response is related to asymmetric dimethylarginine and osteoprotegerin in hypertension. International Journal of Cardiology, 2011, 153, 116-118.	1.7	0
146	Left ventricular hypertrophy: not so much determinant of renal outcome?. Journal of Hypertension, 2011, 29, 622.	0.5	0
147	Response to "Circadian Blood Pressure and Target Organ Damage: More Is Needed― American Journal of Hypertension, 2011, 24, 858-858.	2.0	0
148	The New Anticoagulant Drugs: Are They Really Superior to Warfarin?. Journal of Clinical Hypertension, 2012, 14, 727-727.	2.0	0
149	Which Is the Endotheliumâ€Dependent "Fair Sex―in Hypertension?. Journal of Clinical Hypertension, 2012, 14, 493-495.	2.0	0
150	Renal denervation. Cardiovascular Endocrinology, 2013, 2, 77-84.	0.8	0
151	Combined Exercise Training in Postmenopausal Women: Implications for Vascular Hemodynamics. Journal of Clinical Hypertension, 2013, 15, 221-223.	2.0	0
152	A Patientâ€Centric Webâ€Based Approach to Improve Hypertension Management: A Lesson Learned From Postmenopausal Women. Journal of Clinical Hypertension, 2013, 15, 528-529.	2.0	0
153	Weight and Blood Pressure Changes in High Vascular Risk Patients. Journal of Clinical Hypertension, 2013, 15, 453-454.	2.0	0
154	One‥ear Vascular Adaptations Following Pregnancies Complicated by Hypertension. Journal of Clinical Hypertension, 2014, 16, 700-700.	2.0	0
155	Genomic Research in Postmenopausal Hypertension. Journal of Clinical Hypertension, 2015, 17, 557-557.	2.0	0
156	Longâ€ŧerm safety of different antihypertensive regimens: The risk of unfair comparisons. Journal of Clinical Hypertension, 2018, 20, 201-201.	2.0	0
157	A2788 Antihypertensive drug treatment discontinuation in elderly and very elderly patients undergoing surgery. Journal of Hypertension, 2018, 36, e137-e138.	0.5	Ο
158	Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)― Circulation, 2018, 137,	1.6	0
159	2656-2657. Blood Pressure-Lowering Treatment and the Prevention of Heart Failure: Differences and Similarities of Antihypertensive Drug Classes. Updates in Hypertension and Cardiovascular Protection, 2019, , 285-298.	0.1	0
160	P5464Visit-to-visit glomerular filtration rate variability as a predictor for cardiovascular and renal outcomes in essential hypertension: Data from a Greek 8-year-follow-up study. European Heart Journal, 2019, 40, .	2.2	0
161	P5469Isolated systolic hypertension and combined systolic-diastolic hypertension for prediction of new-onset diabetes mellitus: Data from a 8-year-follow-up study. European Heart Journal, 2019, 40, .	2.2	0
162	P6577Isolated systolic hypertension versus combined systolic-diastolic hypertension as predictors of atrial fibrillation: data from a 8-year-follow-up study. European Heart Journal, 2019, 40, .	2.2	0

#	Article	IF	CITATIONS
163	P805Changes in arterial stiffness independently predict stroke in patients with essential hypertension: Data from a 8-year-follow-up study. European Heart Journal, 2019, 40, .	2.2	0
164	P3409Comparison of the European Society of Hypertension stratification and European Society of Cardiology HeartScore for prediction of coronary artery disease and stroke in essential hypertension. European Heart Journal, 2019, 40, .	2.2	0
165	Network meta-analyses in hypertension. Journal of Hypertension, 2020, 38, 2141-2143.	0.5	0
166	Meta-analysis in hypertension: simple mathematics are always welcome. Journal of Hypertension, 2020, 38, 1861.	0.5	0
167	Reply. Journal of Hypertension, 2021, 39, 385.	0.5	0
168	Net clinical benefit of a reduced dose of DOACs in non-valvular atrial fibrillation: a meta-analysis of randomized trials. Pharmacological Research, 2021, 175, 105902.	7.1	0
169	Safety of Renal Denervation. Updates in Hypertension and Cardiovascular Protection, 2016, , 231-243.	0.1	0
170	ERCP FOR THE TREATMENT OF BILIARY COMPLICATIONS FOLLOWING CHOLECYSTECTOMY. , 2020, 52, .		0
171	Reply. Journal of Hypertension, 2020, 38, 2544-2545.	0.5	0
172	Venous Thromboembolism and Atherosclerotic Events in Patients With Non-Valvular Atrial Fibrillation. Angiology, 2022, , 000331972110473.	1.8	0
173	Prescribing blood pressure lowering drugs irrespective of blood pressure?. Journal of Hypertension, 2022. 40. 1050-1051.	0.5	0